Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Bifidobacterium breve MAK40B22B

What does the research say about Bifidobacterium breve MAK40B22B?

2 health outcomes synthesised

Bifidobacterium breve MAK40B22B has been studied in 6 clinical trials for 2 health outcomes: improved cognitive function and reduced body fat mass. The strongest evidence relates to cognitive function in older adults with mild cognitive impairment, based on 3 randomized controlled trials showing moderate evidence of benefit. Studies typically administered the probiotic for 8–24 weeks, though no specific effective dose was consistently reported.

Strongest evidence: Both researched outcomes have a moderate evidence strength rating. For improved cognitive function, all 3 studies (randomized controlled trials) found small to large beneficial effects in older adults aged 65–88 with mild cognitive impairment or memory complaints. Improvements were observed primarily on memory and global cognition subscales after 16–24 weeks. For reduced body fat mass, 3 studies in pre-obese or obesity-prone adults reported moderate beneficial effects, with 2 of 3 reaching statistical significance at 8–12 weeks.

Mixed or weaker evidence: No outcomes with low or very low evidence strength were available — both synthesized outcomes are rated moderate. However, caveats include small sample sizes (only 3 studies per outcome) and potential publication bias favoring positive results. Effect sizes for cognitive function ranged from small to large, and benefits were seen only on specific cognitive subscales, not across all measures.

Effective dose patterns: No specific effective dose range was consistently reported across studies for either outcome. The syntheses note that dose information was often missing, limiting the ability to recommend specific regimens.

Population insights: Cognitive benefits were studied exclusively in older adults (ages 65–88) with mild cognitive impairment or memory complaints. Reduced body fat mass was studied in healthy pre-obese or obesity-prone adults. No cross-cutting population patterns were evident.

Notable caveats: The evidence base is small (only 3 studies per outcome), making conclusions preliminary. Publication bias is a concern — null results are less likely to be published. Effect sizes varied, and for cognitive function, clinical significance of subscale improvements is unclear. No harmful effects were reported in any study.

Frequently asked

  • What is Bifidobacterium breve MAK40B22B good for according to research?
    Research shows moderate evidence that Bifidobacterium breve MAK40B22B may support improved cognitive function in older adults with mild cognitive impairment and reduced body fat mass in pre-obese or obesity-prone adults. Both findings come from 3 studies each, though the evidence base is small and considered preliminary.
  • What dose of Bifidobacterium breve MAK40B22B is typically used in studies?
    No specific effective dose was consistently reported in the included studies. The syntheses note that dose and form data were often missing, limiting the ability to recommend specific regimens.
  • Who benefits most from Bifidobacterium breve MAK40B22B?
    Cognitive benefits were observed in older adults aged 65–88 with mild cognitive impairment or memory complaints. Reduced body fat mass was studied in healthy adults who were pre-obese or had a tendency for obesity. The research does not indicate benefit in other populations.
  • Does Bifidobacterium breve MAK40B22B help with cognitive function?
    Three randomized controlled trials reported small to large beneficial effects on cognitive function, primarily on memory and global cognition subscales, after 16–24 weeks. However, effects were not seen across all cognitive measures, and the clinical significance of these subscale improvements remains unclear.
  • Does Bifidobacterium breve MAK40B22B help with weight or body fat?
    Three studies found moderate beneficial effects on reduced body fat mass, with 2 of 3 reaching statistical significance. Effects were observed at 8–12 weeks in pre-obese or obesity-prone adults. The evidence is considered moderate but preliminary due to the small number of studies.
  • Are there caveats or limitations in the research on Bifidobacterium breve MAK40B22B?
    Yes. Only 3 studies exist for each outcome, so conclusions are preliminary. There is potential for publication bias favoring positive results. Doses were not consistently reported, and for cognitive function, benefits were limited to specific subscales with unclear clinical significance. No harmful effects were reported.

Most-studied combinations with Bifidobacterium breve MAK40B22B

most supplement research is combination research
Also studied with:Bifidobacterium breve VPro 52 (10)
Back to top